Unlocking Oncogenic Pathway Inhibition as a New Class of ADC Payloads Beyond Classical Cytotoxic Mechanisms
- Examine the scientific rationale for leveraging oncogenic pathway inhibition as an ADC payload strategy, demonstrating how targeted delivery of PI3K/mTOR inhibitors can achieve meaningful anti-tumor activity beyond traditional cytotoxic mechanisms
- Explore preclinical data supporting ADC-enabled delivery of Omipalisib to overcome the systemic toxicities that have historically limited PI3K/mTOR inhibitors, unlocking a previously inaccessible therapeutic window in pathway-addicted tumors
- Define the critical biological and engineering considerations required to optimize non-cytotoxic payloads, including linker-spacer design, conjugation strategy, and the unique pharmacology created by ADC-mediated pathway inhibition